Literature DB >> 24649147

Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.

Hui Li1, Ling Xie1, Ren-Seng Lai1.   

Abstract

Clinical studies suggest that the mRNA expression level of excision repair cross complementing group 1 gene (ERCC1) is associated with epidermal growth factor receptor (EGFR) mutation and breast cancer susceptibility 1 gene (BRCA1) mRNA expression in non-small cell lung cancer (NSCLC). In this study, the correlation between EGFR mutation status and ERCC1 and BRCA1 gene expression in Chinese NSCLC patients was examined. Real-time polymerase chain reaction (PCR) and direct sequencing were used to detect mRNA expression levels and EGFR mutation status, respectively in microdissected formalin-fixed paraffin-embedded non-small cell lung cancer tissues. EGFR mutations were detected in 27/103 patients (26.2%) and were found to be gender-related (P=0.001). The BRCA1 mRNA expression level was associated with histology, while there was no association with ERCC1. For the EGFR mutant-type, a high BRCA1 gene expression was detected in 2 cases (20.0%) and a low expression in 8 cases (80.0%), while for EGFR wild-type, a high BRCA1 gene expression was detected in 20 cases (43.5%) and a low expression in 26 cases (56.5%). There was no difference in the one-year survival period, according to results obtained for either the ERCC1 or BRCA1 mRNA expression levels. EGFR mutations in NSCLC samples are more likely to express low ERCC1 and BRCA1 mRNA levels. In these latter samples, a statistically significant difference was observed. However, to examine their correlation and clinical outcomes, additional studies are required.

Entities:  

Keywords:  breast cancer susceptibility 1 gene; direct sequencing; epidermal growth factor receptor; excision repair cross complementing group 1 gene; non-small cell lung cancer; real-time polymerase chain reaction

Year:  2012        PMID: 24649147      PMCID: PMC3956230          DOI: 10.3892/mco.2012.34

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

Review 1.  Predictive molecular markers in non-small cell lung cancer.

Authors:  R Rosell; M Tarón; A O'Brate
Journal:  Curr Opin Oncol       Date:  2001-03       Impact factor: 3.645

2.  ERCC1 and clinical resistance to platinum-based therapy.

Authors:  Eddie Reed
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

3.  Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.

Authors:  David R Gandara; Peter Grimminger; Philip C Mack; Primo N Lara; Tianhong Li; Peter V Danenberg; Kathleen D Danenberg
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

Review 4.  Predicting the outcome of chemotherapy for lung cancer.

Authors:  Rafael Rosell; Fabiana Cecere; Mariacarmela Santarpia; Noemi Reguart; Miquel Taron
Journal:  Curr Opin Pharmacol       Date:  2006-06-12       Impact factor: 5.547

5.  Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.

Authors:  D Bandyopadhyay; M Mandal; L Adam; J Mendelsohn; R Kumar
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

6.  Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Authors:  Rafael Rosell; Kathleen D Danenberg; Vincente Alberola; Gerold Bepler; Jose Javier Sanchez; Carlos Camps; Mariano Provencio; Dolores Isla; Miquel Taron; Pilar Diz; Angel Artal
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

Authors:  Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

8.  Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.

Authors:  Liping Li; Hong Wang; Eddy S Yang; Carlos L Arteaga; Fen Xia
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Shinichi Toyooka; Nagio Takigawa; Junichi Soh; Yoshiro Fujiwara; Masahiro Tabata; Hiroshi Date; Mitsune Tanimoto
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

Review 10.  The role of BRCA1 in the cellular response to chemotherapy.

Authors:  Richard D Kennedy; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  1 in total

1.  Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis.

Authors:  Ajit Venniyoor; Bassim Al Bahrani
Journal:  Front Oncol       Date:  2016-10-27       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.